comparemela.com

Latest Breaking News On - ஓஹோ ஹாசெட் - Page 1 : comparemela.com

Usio : Partners with Voyager Digital to Enable Merchants and ISVs to Accept Cryptocurrency as a Form of Payment

Usio : Partners with Voyager Digital to Enable Merchants and ISVs to Accept Cryptocurrency as a Form of Payment
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Usio to Participate in the Barrington Research Virtual

Usio to Participate in the Barrington Research Virtual Spring Investment Conference May 24, 2021 09:00 ET | Source: Usio, Inc. Usio, Inc. San Antonio, Texas, UNITED STATES SAN ANTONIO, May 24, 2021 (GLOBE NEWSWIRE) Usio, Inc: (Nasdaq: USIO), a leading FinTech integrated payment solutions provider, today announced it will participate in the Barrington Research Virtual Spring Investment Conference on Thursday, May 27, 2021.   Louis Hoch, Chief Executive Officer, Greg Carter, Senior Vice President, Payment Facilitation and Houston Frost, Senior Vice President, Prepaid Services, will host virtual one-on-one and small group meetings throughout the day. About Usio, Inc. Usio, Inc. (Nasdaq: USIO), a leading FinTech integrated payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus, crypto exchanges and card issuers. The Company operates credit, debit/prepaid, and ACH paym

Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)

Share this article Share this article ENGLEWOOD, Colo., May 10, 2021 /PRNewswire/ Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2. This trial is both needed and exciting in that it addresses a major current and expected ongoing unmet medical need among the estimated 3 to 10 million individuals currently suffering from long COVID, said Michael Macaluso, President and CEO of Ampio.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.